




Don't burn your sperm – Antioxidants and IUI outcome [not all IUI]


Christopher LR Barratt


Reproductive and Developmental Biology,
Medical School,
Dundee,
Scotland

Members of Lab - Marios Stavridis, Senga Overham, Anne Duncan, Wardah Alasmari, Vanessa Kay, Erica Forster, Stephen Mansell, Anne Rice and Cathy Beaton.

MRC  wellcome trust   1








How do we approach treatment?
Identification of the pathology


- Non specific administration of AO to 'sub fertile men' proven to be of no value e.g. Rolf *et al.*, (1999) performed randomised control trial with AO and showed no significant differences with placebo [Hum Reprod 14,1028-
- If identified problem then may be appropriate.
- Problem could be oxidative stress e.g. excessive ROS production or
- more appropriately manifested as increased damage to the sperm e.g. MDA production, DNA damage.
- If these are identified - is there any known benefit?


Potential targeted treatment – promising.

- Kessopoulou *et al* 1995 performed a double blind randomised placebo cross over trial with Vit E [600mg/day] to treat men with high levels of ROS. [Kessopoulou *et al* Fertil Steril 64, 825-831].
- Significant improvement in zona binding (p=0.004) consistent with improvement in plasma membrane of the spermatozoon.
- Sulieman *et al.* 1996 showed significant improvement in motility and pregnancy rates in men with high MDA levels treated with Vit E. [Sulieman *et al.*, 1996 J Androl 17, 530-537.



Journal of Andrology - September/October 1996





One step further to identifying pathology? DNA damage of the cells – treatment works?

- 64 men with high levels of DNA damage randomised with AO vs. placebo treatment. Greco et al., 1996 J Androl 17, 530-537.

Table 2. Comparison of basic sperm parameters and the incidence of DNA fragmentation in the antioxidant treatment group before and after the treatment period.*

Time of Analysis	Sperm Concentration (x 10 ⁶ /mL)	Percent		
		Sperm Motility	Normal Sperm Forms	TUNEL-Positive Spermatozoa
Before treatment	68.8 ± 17.75	40.7 ± 26.14	10.5 ± 6.14	55 ± 7.74
After treatment	27.5 ± 24.64	41.6 ± 22.01	13.0 ± 7.15	9.1 ± 7.23

*Data are mean ± SD. TUNEL indicates terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.
† P > .05.
‡ P < .001.

Interestingly some responders and some non responders.

How do we approach treatment?

Identification of the pathology

- Reasonable data to support *in vivo* administration.
- For *in vitro* administration data less robust
- Great care in preparing cells as those that are susceptible to damage are more 'delicate'.
- NOT a substitute to having high quality systems in place in the beginning – remember many centres have very low IUI success.
- Likely to have a weight of data in next 2-3 years on treatment of 'oxidative stress and DNA damage'
